3630 results for «391»

Filter By

3630 results

Treatment of paravalvular leak

21 Nov 2023 – From PCR London Valves 2023

Explore innovative approaches in paravalvular leak management with this selection of cases: discover the unique strategy of employing three plugs to close a challenging mitral paravalvular leak, navigate the challenges of tackling device migration and retrieval in the closure of a sizable aortic paravalvular leak, gain...

Treatment of paravalvular leak

Mitral valve interventions in challenging clinical situations

21 Nov 2023 – From PCR London Valves 2023

Discover innovative approaches to mitral valve interventions in challenging clinical situations: navigate the challenges of critical stenosis in a bioprosthetic mitral valve, learn more about the use of iVAC-2L in transcatheter edge-to-edge repair for a mitral valve lacking leaflet coaptation, explore mitral transcutaneous edge-to-edge repair guided by transthoracic...

Mitral valve interventions in challenging clinical situations

Second time TAVI (TAV-in-TAV) - Not as simple as it looks

19 Nov 2023 – From PCR London Valves 2023

Although it is still rare, TAV-in-TAV is likely to become more frequent, as TAVI is increasingly implanted in younger patients. Harmonizing data in this area will therefore help to improve outcomes, the quality of which depends on site experience, bearing in mind that for the time...

Second time TAVI (TAV-in-TAV) - Not as simple as it looks

3-year Efficacy Outcomes From the Spyral Htn-on Med Pilot Study: Long Term Effect of Renal Denervation On Blood Pressure Reduction in Patients on Antihypertension Medications

22 Mar 2022

Ali Nazmi Calik provides his take on the long-term results of the SPYRAL HTN-ON MED trial which demonstrated the durable efficacy and safety of RDN in patients who are already on one to three antihypertensive drugs.

Author

Ali Nazmi Calik
3-year Efficacy Outcomes From the Spyral Htn-on Med Pilot Study: Long Term Effect of Renal Denervation On Blood Pressure Reduction in Patients on Antihypertension Medications

EuroPCR 2025 – The FAITAVI trial: angiography versus physiology-guided PCI in patients undergoing TAVI – 12-month follow-up data

21 May 2025

Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among them is the...

EuroPCR 2025 – The FAITAVI trial: angiography versus physiology-guided PCI in patients undergoing TAVI – 12-month follow-up data

GLORIOUS - Efficacy of restrictive versus liberal oxygenation or Exenatide in patients undergoing coronary artery bypass grafting or aortic valve replacement – a randomised clinical trial

21 Nov 2024

Edoardo Zancanaro provides his take on the GLORIOUS trial presented by Sebastian Wiberg at AHA 2024 in Chicago.

Edoardo Zancanaro

Author

Edoardo Zancanaro
GLORIOUS

PCR STATEMENT on evolving indications for transcatheter aortic valve implantation

21 May 2019

Paris, France, 21 May 2019. Severe symptomatic aortic stenosis, a degenerative disease-causing calcification and immobility of the aortic valve leaflets leading to left ventricular outflow obstruction, is the most common valve lesion leading to intervention in Europe and the USA. Symptoms include heart failure, syncope and...

Evolving indications for transcatheter aortic valve implantation

The 2023 ESH Hypertension Guidelines revisit the role of renal denervation

05 Sep 2023

The 2023 European Society of Hypertension (ESH) guidelines were recently presented at the 32nd annual European Meeting on Hypertension and Cardiovascular Protection and simultaneously published in the Journal of Hypertension.1 While wide parts of the guidelines do not substantially differ from the previous 2018 European Society...

Lucas Lauder

Author

Lucas Lauder

Author

Felix Mahfoud
The 2023 ESH Hypertension Guidelines revisit the role of renal denervation

The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation

01 Sep 2025

Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.

Author

Chiara De Biase
The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]

NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome

02 Sep 2025

Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...

Daniele Giacoppo

Author

Daniele Giacoppo
NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome
Didn’t find what you were looking for?